Table 2.
Patient characteristics
| Patient no./sex/age (mo) at diagnosis | Tumour stage at diagnosis₤ | Histologic subtype† | Age-linked classification‡ | VEGF% points§ | VEGF intensity¶ | VEGF score® | Clinical outcome@ |
|---|---|---|---|---|---|---|---|
| 1/m/18 | 2 | 1a | U | 1 | 2 | 3 | S |
| 2/m/36 | 2 | 4 | U | 1 | 1 | 2 | S |
| 3/m/18 | 2 | 1b | F | 2 | 2 | 4 | S |
| 4/m/18 | 2 | 1a | U | 2 | 2 | 4 | S |
| 5/f/37 | 2 | 2 | F | 1 | 1 | 2 | S |
| 6/m/10 | 3 | 1b | F | 1 | 1 | 2 | S |
| 7/f/34 | 2 | 3 | F | 1 | 1 | 2 | S |
| 8/m/121 | 2 | 3 | F | 2 | 2 | 4 | S |
| 9/m/71 | 3 | 3 | F | 1 | 2 | 3 | D* |
| 10/m/3 | 1 | 1a | F | 3 | 2 | 5 | S |
| 11/f/3 | 4s* | 1a | U | 1 | 1 | 2 | S |
| 12/f/33 | 2 | 1a | U | 1 | 2 | 3 | S |
| 13/m/48 | 3 | 1a | U | 4 | 3 | 7 | S |
| 14/m/53 | 3 | 2 | F | 1 | 2 | 3 | S |
| 15/m/18 | 3 | 1a | U | 0 | 0 | 0 | S |
| 16/f/46 | 2 | 2 | F | 2 | 3 | 5 | S |
| 17/f/2 | 2 | 1b | F | 4 | 3 | 7 | S |
| 18/m/78 | 2 | 2 | F | 1 | 1 | 2 | S |
| 19/m/4 | 3 | 1b | F | 2 | 3 | 5 | S |
| 20/m/2 | 2 | 1a | F | 1 | 2 | 3 | S |
| 21/m/2 | 2 | 1a | U | 0 | 0 | 0 | S |
| 22/f/18 | 3 | 1b | F | 1 | 2 | 3 | S |
| 23/f/14 | 2 | 1b | F | 1 | 1 | 2 | S |
| 24/m/72 | 3 | 2 | F | 3 | 3 | 6 | S |
| 25/m/144 | 4 | 1a | U | 2 | 3 | 5 | D |
| 26/f/24 | 4 | 1a | U | 2 | 3 | 5 | D |
| 27/m/120 | 4 | 1a | U | 2 | 3 | 5 | D |
| 28/m/38 | 3 | 2 | F | 2 | 2 | 4 | D |
| 29/m/120 | 4 | 1a | U | 1 | 2 | 3 | D |
| 30/m/35 | 4 | 1a | U | 1 | 2 | 3 | D |
| 31/f/61 | 4 | 1a | U | 2 | 2 | 4 | D |
| 32/m/97 | 2 | 1a | U | 1 | 2 | 3 | D |
| 33/m/84 | 3 | 1b | U | 3 | 2 | 5 | D |
| 34/f/23 | 4 | 1b | U | 2 | 2 | 4 | D |
| 35/f/42 | 4 | 1a | U | 4 | 3 | 7 | D |
| 36/f/5 | 4 | 1a | U | 2 | 3 | 5 | D |
| 37/m/36 | 3 | 1a | U | 3 | 2 | 5 | D |
| 38/f/48 | 4 | 1a | U | 4 | 3 | 7 | D |
| 39/m/10 | 4 | 1a | U | 1 | 2 | 3 | D |
| 40/f/122 | 2 | 1a | U | 1 | 1 | 2 | S |
| 41/m/38 | 4 | 1a | U | 3 | 3 | 6 | S |
| 42/f/35 | 3 | 2 | F | 1 | 4 | 6 | S |
| 43/m/30 | 1 | 2 | U | 1 | 1 | 2 | S |
| 44/m/3 | 4 | 1b | F | 2 | 2 | 4 | S |
| 45/f/12 | 4 | 1b | F | 2 | 3 | 5 | S |
| 46/f/17 | 3 | 1a | U | 2 | 3 | 5 | S |
| 47/m/18 | 4 | 1a | U | 2 | 3 | 5 | S |
| 48/m/36 | 3 | 2 | F | 1 | 1 | 2 | S |
| 49/m/66 | 4 | 1b | U | 1 | 2 | 3 | S |
| 50/m/12 | 4 | 1a | F | 2 | 3 | 5 | S |
| 51/m/36 | 3 | 2 | F | 3 | 2 | 5 | S |
| 52/f/35 | 4 | 4 | U | 1 | 3 | 4 | D |
| 53/f/54 | 4 | 1a | U | 1 | 2 | 3 | D |
| 54/m/54 | 4 | 4 | U | 2 | 3 | 5 | D |
| 55/m/60 | 3 | 1a | U | 3 | 1 | 4 | D |
| 56/f/56 | 4 | 1b | U | 1 | 2 | 3 | D |
₤ Tumour staging at diagnosis according to INSS25;
† Shimada histopathologic classification26 1a: Stroma poor, undifferentiated; 1b: Stroma poor, differentiating; 2: Stroma rich, intermixed; 3: Stroma rich, well differentiated; 4: Stroma rich, focal nodular
‡ Prognostic groups according to the age-linked classification of Shimada26 F: favourable; U: unfavourable;
§VEGF % (percentage of positive VEGF cells) 0 point: <1% positive cells, 1 point: 1-25% positive cells; 2 points: 26-50% positive cells; 3 points: 51-75% positive cells; 4 points: 76-100% positive cells
¶VEGF intensity (staining intensity) 1: weak intensity; 2: moderate intensity; 3: strong intensity
® VEGF score: points for staining intensity and percentage of positive cells were added
@ S: surviving, D: dead, D*: one patient died in relapse of tumour 5,5 yr after diagnosis
4S* in a infant with small primary tumour and metastatic disease involving the skin, liver, limited infiltration of the bone marrow